• Title/Summary/Keyword: Target therapy

Search Result 21, Processing Time 0.092 seconds

Target Therapy for Colorectal Cancer (대장암의 표적치료)

  • Lee, Kyung-Hee
    • Yeungnam University Journal of Medicine
    • /
    • v.23 no.2
    • /
    • pp.143-151
    • /
    • 2006
  • In the past decade, the median duration of survival among patients with advanced colorectal cancer has increased from 12 months to about 18 months, primarily as a results of the introduction of irinotecan and oxaliplatin. Advances in the understanding of the molecular mechanisms underlying the development and progression of cancer have resulted in the discovery of new therapeutic interventions that target specific molecular abnormalities. Their specificity, and therefore their potential to bind preferentially and modify tumor-specific targets, sparing normal tissues and causing fewer side-effects compared to conventional cytotoxic agents, makes them an attractive therapeutic option. The future of this approach for the treatment of solid tumors is promising.

  • PDF

Overview of Helicobacter pylori and Treatment Options (헬리코박터 파일로리(Helicobacter pylori) 감염 및 치료법 개요)

  • Song, Young Goo
    • Economic and Environmental Geology
    • /
    • v.48 no.3
    • /
    • pp.241-246
    • /
    • 2015
  • Helicobacter pylori is an important transmissible human pathogen found on the luminal surface of the gastric epithelium. The organism can persist in the stomach indefinitely and causes gastroduodenal inflammation that may proceed to atrophic gastritis, peptic ulcer, gastric MALT lymphoma, and gastric cancer. Standard triple therapy which consists of proton pump inhibitor (PPI) plus two antibiotics (amoxicillin and clarithromycin) is now generally used in Korea, however, eradication rates of H. pylori has been decreasing due to increasing antibiotic resistance. In this review, current second-line treatment regimens, difficult problems on treatment, necessity of local target therapy, applicability of clay minerals as a drug delivery system (DDS), and a new therapeutic strategy and its study plans will be discussed.

Cutaneous melanoma (피부흑색종)

  • Lee, Seok-Jong;Lee, Soo Jung
    • Journal of the Korean Medical Association
    • /
    • v.61 no.11
    • /
    • pp.662-669
    • /
    • 2018
  • The cutaneous melanoma has been regarded as rare disease entity in Korea for long time but it shows a silent growth recently. Furthermore the management of cutaneous melanoma including staging system, surgical principle, sentinel lymph node biopsy and subsequent complete node dissection and, most importantly, immunotherapy and target therapy against cutaneous melanoma recently. The incidence of cutaneous melanoma is steadily increasing in Korea but its increase is rapid recent 2 decades to 4.3 times and should be greater soon according to the steeper increase of life expectancy. New staging system proposed by American Joint Committee on Cancer (2017) includes changes in individual TNM category and stage groups, particularly from a prognostic viewpoint. Dermoscopy has been successfully introduced in the differential diagnosis of pigmented skin lesion focusing on cutaneous melanoma by non-invasive simple diagnostic tool. Sentinel lymph node biopsy was a issue of long debate whether survival benefit is real or not. Temporary conclusion about this question is reached after two large scale studies and immediate complete node dissection should be performed in a certain situations. Most important change is drug therapy focusing on immunotherapy and target therapy. Braf- and MEK-inhibitor, immune checkpoint inhibitor and PD-1 blocker has been proved to be effective as a sole or combination regimen against advanced and/or high-risk adjuvant setting of cutaneous melanoma. In conclusion, these remarkable changes will be reviewed shortly here.

Molecular Diagnosis for Personalized Target Therapy in Gastric Cancer

  • Cho, Jae Yong
    • Journal of Gastric Cancer
    • /
    • v.13 no.3
    • /
    • pp.129-135
    • /
    • 2013
  • Gastric cancer is the second leading cause of cancer-related deaths worldwide. In advanced and metastatic gastric cancer, the conventional chemotherapy with limited efficacy shows an overall survival period of about 10 months. Patient specific and effective treatments known as personalized cancer therapy is of significant importance. Advances in high-throughput technologies such as microarray and next generation sequencing for genes, protein expression profiles and oncogenic signaling pathways have reinforced the discovery of treatment targets and personalized treatments. However, there are numerous challenges from cancer target discoveries to practical clinical benefits. Although there is a flood of biomarkers and target agents, only a minority of patients are tested and treated accordingly. Numerous molecular target agents have been under investigation for gastric cancer. Currently, targets for gastric cancer include the epidermal growth factor receptor family, mesenchymal-epithelial transition factor axis, and the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathways. Deeper insights of molecular characteristics for gastric cancer has enabled the molecular classification of gastric cancer, the diagnosis of gastric cancer, the prediction of prognosis, the recognition of gastric cancer driver genes, and the discovery of potential therapeutic targets. Not only have we deeper insights for the molecular diversity of gastric cancer, but we have also prospected both affirmative potentials and hurdles to molecular diagnostics. New paradigm of transdisciplinary team science, which is composed of innovative explorations and clinical investigations of oncologists, geneticists, pathologists, biologists, and bio-informaticians, is mandatory to recognize personalized target therapy.

Skull Metastasis of Gastric Gastrointestinal Stromal Tumor Successfully Managed by Surgery

  • Park, Inkeun;Chung, Dong Hae;Yoo, Chan Jong;Shin, Dong Bok
    • Journal of Korean Neurosurgical Society
    • /
    • v.60 no.1
    • /
    • pp.94-97
    • /
    • 2017
  • Gastrointestinal stromal tumors (GISTs) are rare, but are the most common mesenchymal neoplasm of the gastrointestinal tract. The most common sites of metastasis are liver and peritoneum, while bone metastasis is rare. We report on a patient with skull metastasis after seven years of treatment with imatinib for metastatic GIST. She underwent metastasectomy consisting of craniectomy with excision of the mass, and cranioplasty and continued treatment with imatinib and sunitinib, without evidence of cranial recurrence. She died of pneumonia sepsis one year after metastasectomy. Skull metastasis of GIST is a very rare presentation, and an aggressive multidisciplinary approach should be considered whenever possible.

Research Progress on the Livin Gene and Osteosarcomas

  • Li, Cheng-Jun;Cong, Yu;Liu, Xiao-Zhou;Zhou, Xing;Shi, Xin;Wu, Su-Jia;Zhou, Guang-Xin;Lu, Meng
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.15 no.20
    • /
    • pp.8577-8579
    • /
    • 2014
  • Osteosarcoma is a common malignant tumor of bone, but mechanisms underlying its development are still unclear. At present, it is believed that the inhibition of normal apoptotic mechanisms is one of the reasons for the development of tumors, so specific stimulation of tumor cell apoptosis can be considered as an important therapeutic method. Livin, as a member of the newly discovered inhibitor of apoptosis proteins (IAPs) family, has specifically high expression in tumor tissues and can inhibit tumor cell apoptosis through multiple ways, which can become a new target for malignant tumor treatment (including osteosarcoma) and might of great significance in the clinical diagnosis of tumors and the screening of anti-tumor agents and carcinoma treatment.

Systemic Therapy for Advanced and Metastatic Colon Cancer (진행성 및 전이성 대장암에서의 전신 항암 치료)

  • Park, Jae Jun
    • The Korean Journal of Gastroenterology
    • /
    • v.73 no.4
    • /
    • pp.202-206
    • /
    • 2019
  • Colon cancer is one of the three most common cancers in both men and women in Organization for Economic Cooperation and Development countries. Approximately one-quarter of colon cancer patients have a metastasis at the time of diagnosis, and systemic therapy is used in many of them as a first line therapy. In addition to existing cytotoxic drugs, target therapy has been introduced in colon cancer and immunotherapy has shown clinical benefits in the treatment of metastatic colon cancer. The purpose of this review was to briefly summarize the National Comprehensive Cancer Network guidelines for systemic therapy in colon cancer with special reference to targeted agents and novel agents.

Leukemia Stem Cells in Blood Cells; Focused on Acute Myeloid Leukemia

  • Lee, Ji Yoon
    • Biomedical Science Letters
    • /
    • v.23 no.1
    • /
    • pp.1-7
    • /
    • 2017
  • It is known that acute myeloid leukemia (AML) is a heterogeneous blood cancer, which is enormously propagated by self-renewing leukemia stem cells (LSCs). The persistence of LSCs after chemotherapy can contribute to minimal residual disease and relapse by LSCs can be evoked promptly. Elucidating special molecules and cellular activity of LSCs is an extremely important to eliminate AML. Despite an increasing understanding of the origin of LSCs by incessant study, AML still remains a notorious disease with high mortality. An exact identification of the LSCs that sustain the proliferation of neoplastic clone is a fundamental issue in AML treatment. CD34+CD38- conventional phenotype is overall regarded as LSCs, but it has a limitation that is still hard to demarcate exactly due to similarity with normal hematopoietic stem cells (HSCs). Not all primary blasts and progenitors have equal function, thus a bona fide marker for identifying LSCs from HSCs is needed in hematologic malignancy, especially in AML. These findings have direct important implications in both in mechanistic study of LSCs as well as in the strategies of more effective therapies. In this review, I briefly summarized current advances in LSCs biology, focusing on membrane markers and a functional behavior of LSCs in AML treatment with monoclonal antibodies. Ultimately, it may be helpful in overviewing the status of LSC research, while expecting the clinic benefits of target therapy by specific inhibition.

In vitro Susceptibility of the Six Malassezia Species to Itraconazole, Fluconazole and Terbinafine (말라세지아 균주 6종에 대한 항진균제 시험관내 감수성 시험)

  • Lee, Yangwon
    • Journal of Mycology and Infection
    • /
    • v.22 no.1
    • /
    • pp.21-27
    • /
    • 2017
  • Background: Malasseiza species are dimorphic and lipophilic fungi which are part of normal mycota of the human skin, and also associated with some skin diseases. In many skin diseases such as pityriasis versicolor, Malassezia folliculitis, seborrheic dermatitis, atopic dermatitis and psoriasis, Malassezia yeasts may have a key role. Objective: To investigate susceptibility of antifungal agent including itraconazole, fluconazole and terbinafine, we conducted in vitro susceptibility test revealing minimum inhibitory concentration of drugs for each Malassezia strains. Methods: Malassezia restricta CBS7877, M. globosa CBS 7966, M. slooffiae KCTC 27517, M. sympodialis CBS 7222, M. pachydermatis CBS 1879 and M. furfur CBS 1878 were used in this experiment. The strains were grown in Leeming and Notman medium. MIC was determined using the method suggested by Sugita, et al. with modification. Malassezia cells were grown in each well and incubated for 2 days at $34^{\circ}C$, and MIC was determined by agar dilution method. Results: Most Malasseiza strains of all Malassezia species were most sensitive to itraconazole, with MICs ranging from 0.015 to $0.06{\mu}g/mL$. MIC values of fluconazole and terbinafine against Malassezia species were higher and wider range than MIC of itraconazole. Conclusion: Itracozanole would be the first choice drug for treatment of Malassezia associated skin diseases. Isolation of pathologic species of Malassezia from various skin diseases in Korea would be fundamental research for the target therapy, and drug susceptibility test would be helpful for proper treatment.

Recent Trends of Lung Cancer in Korea

  • Lee, Jae Guk;Kim, Ho Cheol;Choi, Chang-Min
    • Tuberculosis and Respiratory Diseases
    • /
    • v.84 no.2
    • /
    • pp.89-95
    • /
    • 2021
  • Lung cancer is one of the leading causes of cancer-related deaths in Korea. Although the smoking rate has decreased over time, the prevalence of lung cancer still remains high. In this study, we reviewed recent trends on the incidence, epidemiology, screening, diagnosis, and treatment of lung cancer in Korea by analyzing data from the national lung cancer registry and recently-published studies. Although approximately 40% of patients with non-small cell lung cancer (NSCLC) were diagnosed as stage IV, the 5-year relative survival rate improved from 11.3% (1993-1995) to 30.2% (2013-2017), possibly due to advances in methods of diagnosis and therapy. In addition, the 2019 implementation of the national lung cancer screening program with low-dose computed tomography may have also contributed to these improvements in survival rates. Recently, molecular diagnosis has become more widely used in the identification of genetic mutations in tissue specimens. Target therapy and immune checkpoint inhibitors have also been successfully used, particularly in cases of advanced NSCLC. In the future, further research on the optimal management of lung cancer remains necessary.